<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5261">
  <stage>Registered</stage>
  <submitdate>25/09/2015</submitdate>
  <approvaldate>25/09/2015</approvaldate>
  <nctid>NCT02561962</nctid>
  <trial_identification>
    <studytitle>A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma</studytitle>
    <scientifictitle>A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20130314</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AMG 224

Experimental: Dose Exploration - 


Treatment: drugs: AMG 224
AMG 224 will be given on Day 1 once every 3 weeks with dose ranging from 30 mg to 300 mg.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety: Incidence of dose limiting toxicities (DLTs), treatment-related, treatment-emergent</outcome>
      <timepoint>3 years</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Pathologically documented,multiple myeloma relapsed or refractory progressive disease
        after at least 3 lines of therapy for multiple myeloma.

        Prior therapeutic treatment or regimens must include proteasome inhibitors (e.g.
        bortezomib) and immunomodulatory drugs (e.g. lenalidomide).

          -  Willing and able to undergo bone marrow aspirate per protocol (with or without bone
             marrow biopsy per institutional guidelines).

          -  Measurable disease per the IMWG response criteria

          -  Hematological function, as follows, without transfusion support:

          -  Absolute neutrophil count = 1.0 X 10 9/L,

          -  Platelet count = 75 X 109/L (in patients with &lt; 50% of bone marrow nucleated cells
             were plasma cells) or = 50 X 109/L (in patients with = 50% of bone marrow nucleated
             cells were plasma cells) without transfusion or growth factor support

          -  Hemoglobin &gt; 8 g/dL (&gt; 80 g/L)

          -  Adequate renal and hepatic function

          -  Left ventricular ejection fraction (LVEF) &gt; 50%</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Currently receiving treatment in another investigational device or drug study, or less
             than 28 days since ending treatment on another investigational device or drug study

          -  Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or
             investigational agent) within 28 days prior to study day 1

          -  Multiple myeloma with IgM subtype

          -  Glucocorticoid therapy (prednisone &gt; 30 mg/day or equivalent) within 7 days prior to
             study day

          -  Autologous stem cell transplant less than 90 days prior to study day 1

          -  POEMS syndrome, Plasma cell leukemia, Waldenstrom's macroglobulinemia or Amyloidosis

          -  Myocardial infarction within 6 months of study day 1, symptomatic congestive heart
             failure (New York Heart Association &gt; class II)

          -  A baseline ECG QTcF &gt; 470 msec</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>20/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>13/03/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Research Site - Prahran</hospital>
    <postcode>3181 - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a first in human phase 1 multicenter open label study in subjects with relapsed or
      refractory multiple myeloma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02561962</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Amgen Call Center</name>
      <address />
      <phone>866-572-6436</phone>
      <fax />
      <email>medinfo@amgen.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>